Table 1. Comparison of the microarray datasets used to assess the association of gene to response against anti-HER2 therapy.
| Dataset | Affymetrix dataset | Agilent dataset | [57] |
|---|---|---|---|
| n | 50 | 11 | 27 |
| Platform | GPL96 | GPL1708 | GPL5325 |
| Clinical characteristics | |||
| - Mean age (years) | 49.42 | 47.43 | n.a. |
| - Lymph node positive (%) | 15 (29.4%) | n.a. | n.a. |
| - ER status (negative %) | 64% | 55% | 56% |
| - PR status (negative %) | 74% | 64% | 70% |
| - HER2 status (%) | Positive (100%) | Positive (100%) | Positive (100%) |
| Treatment characteristics | |||
| - Anti-HER2 therapy | Trastuzumab (100%) | Trastuzumab (100%) | Trastuzumab (100%) |
| - Chemotherapy (%) | FEC+T (100%) | AC+T (100%) | D+C (100%) |
| - Response (%) | 48% | 45.5% | 37% |
doxorubicin + cyclophosphamide + taxane=AC+T; docetaxel + capecitabine=DC; FEC+Taxol=FEC+T.